Bioventix (BVXP) Competitors

GBX 1,700 0.00 (0.00%)

As of 05/15/2026 12:25 PM Eastern

BVXP vs. PRTC, HZD, VRP, BTG, and ARIX

Should you buy Bioventix stock or one of its competitors? MarketBeat compares Bioventix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bioventix include PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), BTG (BTG), and Arix Bioscience (ARIX). These companies are all part of the "biotechnology" industry.

How does Bioventix compare to PureTech Health?

Bioventix (LON:BVXP) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Bioventix has a net margin of 59.30% compared to PureTech Health's net margin of -2,355.32%. Bioventix's return on equity of 65.83% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventix	59.30%	65.83%	54.07%
PureTech Health	-2,355.32%	-31.98%	-13.39%

PureTech Health has a consensus target price of GBX 508, indicating a potential upside of 285.43%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts clearly believe PureTech Health is more favorable than Bioventix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Bioventix has a beta of 0.484, suggesting that its share price is 52% less volatile than the broader market. Comparatively, PureTech Health has a beta of 1.399308, suggesting that its share price is 40% more volatile than the broader market.

Bioventix has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventix	£12.54M	7.08	£8.12M	£140.52	12.10
PureTech Health	£4.66M	68.86	-£91.86M	-£46.00	N/A

In the previous week, Bioventix and Bioventix both had 1 articles in the media. Bioventix's average media sentiment score of 0.00 equaled PureTech Health'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

21.1% of Bioventix shares are owned by institutional investors. Comparatively, 34.6% of PureTech Health shares are owned by institutional investors. 6.2% of Bioventix shares are owned by insiders. Comparatively, 13.4% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Bioventix and PureTech Health tied by winning 7 of the 14 factors compared between the two stocks.

How does Bioventix compare to Horizon Discovery Group plc (HZD.L)?

Bioventix (LON:BVXP) and Horizon Discovery Group plc (HZD.L) (LON:HZD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

21.1% of Bioventix shares are held by institutional investors. 6.2% of Bioventix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Bioventix has a net margin of 59.30% compared to Horizon Discovery Group plc (HZD.L)'s net margin of 0.00%. Bioventix's return on equity of 65.83% beat Horizon Discovery Group plc (HZD.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventix	59.30%	65.83%	54.07%
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A

Bioventix has higher earnings, but lower revenue than Horizon Discovery Group plc (HZD.L). Horizon Discovery Group plc (HZD.L) is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventix	£12.54M	7.08	£8.12M	£140.52	12.10
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A

In the previous week, Bioventix had 1 more articles in the media than Horizon Discovery Group plc (HZD.L). MarketBeat recorded 1 mentions for Bioventix and 0 mentions for Horizon Discovery Group plc (HZD.L). Bioventix's average media sentiment score of 0.00 equaled Horizon Discovery Group plc (HZD.L)'saverage media sentiment score.

Company	Overall Sentiment
Bioventix	Neutral
Horizon Discovery Group plc (HZD.L)	Neutral

Summary

Bioventix beats Horizon Discovery Group plc (HZD.L) on 8 of the 9 factors compared between the two stocks.

How does Bioventix compare to Verona Pharma plc (VRP.L)?

Bioventix (LON:BVXP) and Verona Pharma plc (VRP.L) (LON:VRP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Bioventix has a net margin of 59.30% compared to Verona Pharma plc (VRP.L)'s net margin of 0.00%. Bioventix's return on equity of 65.83% beat Verona Pharma plc (VRP.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventix	59.30%	65.83%	54.07%
Verona Pharma plc (VRP.L)	N/A	N/A	N/A

Bioventix has higher revenue and earnings than Verona Pharma plc (VRP.L). Verona Pharma plc (VRP.L) is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventix	£12.54M	7.08	£8.12M	£140.52	12.10
Verona Pharma plc (VRP.L)	N/A	N/A	N/A	-£32.70	N/A

In the previous week, Bioventix had 1 more articles in the media than Verona Pharma plc (VRP.L). MarketBeat recorded 1 mentions for Bioventix and 0 mentions for Verona Pharma plc (VRP.L). Bioventix's average media sentiment score of 0.00 equaled Verona Pharma plc (VRP.L)'saverage media sentiment score.

Company	Overall Sentiment
Bioventix	Neutral
Verona Pharma plc (VRP.L)	Neutral

Summary

Bioventix beats Verona Pharma plc (VRP.L) on 9 of the 9 factors compared between the two stocks.

How does Bioventix compare to BTG?

BTG (LON:BTG) and Bioventix (LON:BVXP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

Bioventix has a net margin of 59.30% compared to BTG's net margin of 0.00%. Bioventix's return on equity of 65.83% beat BTG's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BTG	N/A	N/A	N/A
Bioventix	59.30%	65.83%	54.07%

BTG pays an annual dividend of GBX 4.30 per share and has a dividend yield of 3.7%. Bioventix pays an annual dividend of GBX 150 per share and has a dividend yield of 8.8%. BTG pays out 71.7% of its earnings in the form of a dividend. Bioventix pays out 106.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Bioventix has lower revenue, but higher earnings than BTG. Bioventix is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BTG	£159.40M	1.19	N/A	£6.00	19.58
Bioventix	£12.54M	7.08	£8.12M	£140.52	12.10

BTG currently has a consensus price target of GBX 160, suggesting a potential upside of 36.17%. Given BTG's stronger consensus rating and higher probable upside, equities analysts clearly believe BTG is more favorable than Bioventix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BTG	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Bioventix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

19.3% of BTG shares are owned by institutional investors. Comparatively, 21.1% of Bioventix shares are owned by institutional investors. 19.8% of BTG shares are owned by insiders. Comparatively, 6.2% of Bioventix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, BTG had 2 more articles in the media than Bioventix. MarketBeat recorded 3 mentions for BTG and 1 mentions for Bioventix. Bioventix's average media sentiment score of 0.00 beat BTG's score of -0.28 indicating that Bioventix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BTG	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Bioventix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BTG and Bioventix tied by winning 8 of the 16 factors compared between the two stocks.

How does Bioventix compare to Arix Bioscience?

Bioventix (LON:BVXP) and Arix Bioscience (LON:ARIX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

21.1% of Bioventix shares are owned by institutional investors. Comparatively, 41.3% of Arix Bioscience shares are owned by institutional investors. 6.2% of Bioventix shares are owned by company insiders. Comparatively, 20.7% of Arix Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Arix Bioscience has higher revenue and earnings than Bioventix. Arix Bioscience is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventix	£12.54M	7.08	£8.12M	£140.52	12.10
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A

Bioventix has a beta of 0.484, suggesting that its share price is 52% less volatile than the broader market. Comparatively, Arix Bioscience has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

Arix Bioscience has a net margin of 105.64% compared to Bioventix's net margin of 59.30%. Bioventix's return on equity of 65.83% beat Arix Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventix	59.30%	65.83%	54.07%
Arix Bioscience	105.64%	6.41%	2.18%

In the previous week, Bioventix had 1 more articles in the media than Arix Bioscience. MarketBeat recorded 1 mentions for Bioventix and 0 mentions for Arix Bioscience. Bioventix's average media sentiment score of 0.00 equaled Arix Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Bioventix	Neutral
Arix Bioscience	Neutral

Summary

Arix Bioscience beats Bioventix on 7 of the 11 factors compared between the two stocks.

Get Bioventix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BVXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BVXP vs. The Competition

Export

Metric	Bioventix	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£88.82M	£466.99M	£6.43B	£2.60B
Dividend Yield	8.82%	3.86%	2.80%	6.15%
P/E Ratio	12.10	3.87	20.38	365.91
Price / Sales	7.08	7,766.11	566.19	88,030.08
Price / Cash	30.89	13.13	43.04	27.89
Price / Book	7.39	84.21	9.87	7.74
Net Income	£8.12M	-£96.07M	£3.57B	£5.89B
7 Day Performance	-0.47%	0.98%	0.31%	0.21%
1 Month Performance	-3.95%	0.43%	-1.27%	1.56%
1 Year Performance	-39.29%	69.18%	33.54%	77.95%

Bioventix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BVXP Bioventix	N/A	GBX 1,700 flat	N/A	-40.1%	£88.82M	£12.54M	12.10	12	News Coverage
PRTC PureTech Health	1.4531 of 5 stars	GBX 127.20 -0.6%	GBX 508 +299.4%	+3.0%	£309.63M	£4.66M	N/A	300	News Coverage
HZD Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A	N/A	£302.98M	£54.63M	N/A	416
VRP Verona Pharma plc (VRP.L)	N/A	N/A	N/A	N/A	£228M	N/A	N/A	22	Gap Up
BTG BTG	3.7415 of 5 stars	GBX 120 +0.4%	GBX 160 +33.3%	N/A	£192.47M	£159.40M	20.00	4,690

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:BVXP) was last updated on 5/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bioventix (BVXP) Competitors

BVXP vs. PRTC, HZD, VRP, BTG, and ARIX

How does Bioventix compare to PureTech Health?

Summary

How does Bioventix compare to Horizon Discovery Group plc (HZD.L)?

Summary

How does Bioventix compare to Verona Pharma plc (VRP.L)?

Summary

How does Bioventix compare to BTG?

Summary

How does Bioventix compare to Arix Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVXP vs. The Competition

Bioventix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bioventix (BVXP) Competitors

BVXP vs. PRTC, HZD, VRP, BTG, and ARIX

How does Bioventix compare to PureTech Health?

Is BVXP or PRTC more profitable?

Do analysts rate BVXP or PRTC?

Which has more risk and volatility, BVXP or PRTC?

Which has better valuation and earnings, BVXP or PRTC?

Does the media prefer BVXP or PRTC?

Do insiders & institutionals believe in BVXP or PRTC?

Summary

How does Bioventix compare to Horizon Discovery Group plc (HZD.L)?

Do institutionals and insiders have more ownership in BVXP or HZD?

Is BVXP or HZD more profitable?

Which has preferable earnings & valuation, BVXP or HZD?

Does the media prefer BVXP or HZD?

Summary

How does Bioventix compare to Verona Pharma plc (VRP.L)?

Is BVXP or VRP more profitable?

Which has preferable earnings & valuation, BVXP or VRP?

Do institutionals and insiders have more ownership in BVXP or VRP?

Does the media prefer BVXP or VRP?

Summary

How does Bioventix compare to BTG?

Is BTG or BVXP more profitable?

Is BTG or BVXP a better dividend stock?

Which has better earnings & valuation, BTG or BVXP?

Do analysts rate BTG or BVXP?

Do insiders and institutionals believe in BTG or BVXP?

Does the media favor BTG or BVXP?

Summary

How does Bioventix compare to Arix Bioscience?

Do institutionals & insiders believe in BVXP or ARIX?

Which has preferable earnings & valuation, BVXP or ARIX?

Which has more volatility & risk, BVXP or ARIX?

Is BVXP or ARIX more profitable?

Does the media prefer BVXP or ARIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVXP vs. The Competition

Bioventix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools